42 results match your criteria: "Kichijoji Asahi Hospital[Affiliation]"

Article Synopsis
  • * A total of 103 patients, mostly with stenotic issues in the upper arm, showed high technical and clinical success rates, with favorable patency rates at 6 months.
  • * The research found low rates of adverse events (≤3%) and no device deficiencies, supporting the use of this stent graft as a safe and effective option for patients experiencing vascular access graft problems.
View Article and Find Full Text PDF
Article Synopsis
  • This study focused on understanding the clinical features and treatment outcomes of Japanese patients newly diagnosed with Takayasu arteritis (TAK) during the initial two years of their treatment.
  • A total of 129 patients were analyzed, with a majority being women, and common clinical symptoms related to large-vessel lesions, particularly in areas like the carotid and subclavian arteries.
  • The results highlighted that 82.9% of patients achieved clinical remission at 24 weeks, but only 39.5% maintained it at 52 weeks, with large-vessel symptoms linked to poorer outcomes for sustained remission.*
View Article and Find Full Text PDF

Background: The effects of tonsillectomy combined with steroid pulse (TSP) therapy for IgA nephropathy (IgAN) are little known. Therefore, we examined the effects of TSP therapy on the kidney outcomes of IgAN in a large, nationwide cohort study in Japan.

Methods: Between 2002 and 2004, 632 IgAN patients with ≥ 0.

View Article and Find Full Text PDF

Analysis of the impact of obesity on the prognosis of IgA nephropathy according to renal function and sex.

Clin Exp Nephrol

November 2024

Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.

Article Synopsis
  • A study explored how obesity affects kidney outcomes specifically in patients with immunoglobulin A nephropathy (IgAN), considering factors such as sex and kidney function.
  • Researchers analyzed data from patients in Japan, categorizing them into normal and obese groups based on body mass index (BMI), and focused on renal function decline and the need for replacement therapy.
  • Findings indicated that while obesity didn't show a direct impact on kidney prognosis, it was linked to having more risk factors for IgAN progression, particularly affecting women in terms of proteinuria and contributing to kidney damage like tubular atrophy.
View Article and Find Full Text PDF

Objective: This study aimed to evaluate the Ministry of Health, Labour and Welfare (MHLW) diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to the new American College of Rheumatology/European Alliance of Associations for Rheumatology 2022 criteria.

Methods: Two nationwide cohort studies were used, and participants were categorised as having eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA) according to the American College of Rheumatology/European Alliance of Associations for Rheumatology 2022 and MHLW criteria.

Results: Of the entire patient population, only 10 (2.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate the impact of low-protein diets (LPD) on kidney function and overall health in patients with chronic kidney disease (CKD) stages 4 and 5.
  • It involved 325 patients, categorized into four groups based on their daily protein intake, and monitored outcomes such as the initiation of renal replacement therapy (RRT) and mortality over an average follow-up of 4.1 years.
  • Results indicated that a non-supplemented LPD of 0.5 g/kg/day or less was associated with a lower risk of needing RRT and reduced all-cause mortality in these patients.
View Article and Find Full Text PDF

Objectives: This study elucidated the prognosis and risk factors associated with damage accrual during long-term remission maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

Methods: We obtained data from 120 patients registered in a nationwide prospective cohort study on remission induction therapy in Japanese patients with AAV and rapidly progressive glomerulonephritis (RemIT-JAV-RPGN), who achieved remission at 24 months after treatment initiation and were followed up for additional 24 months. The primary outcome was the vasculitis damage index (VDI) score at Month 48, and the secondary outcome included risk factors associated with increased total VDI at Month 48.

View Article and Find Full Text PDF

Background: Disease relapse remains a major problem in the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). In European populations, is associated with both susceptibility and relapse risk in proteinase 3-ANCA positive AAV. In a Japanese population, we previously reported an association between and with susceptibility to, and with protection from, myeloperoxidase-ANCA positive AAV (MPO-AAV).

View Article and Find Full Text PDF

Objective: The objective of this study was to compare the American College of Rheumatology/European Alliance of Associations for Rheumatology 2022 criteria with the previous classification algorithm for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Methods: We used data from two nationwide, prospective, inception cohort studies. The enrolled patients were classified as having eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA) according to the new criteria; these criteria were compared with Watts' algorithm.

View Article and Find Full Text PDF

Background: Clinical factors affecting renal prognosis in patients with immunoglobulin A nephropathy (IgAN) and low urinary protein excretion (U-Prot) remain unclear. This study evaluated such factors in patients with clinical grade I (CG-I) IgAN with U-Prot < 0.5 g/day.

View Article and Find Full Text PDF

Background: Neutrophil extracellular traps (NETs) are critically involved in microscopic polyangiitis (MPA) pathogenesis, and some patients with MPA possess anti-NET antibody (ANETA). Anti-myosin light chain 6 (MYL6) antibody is an ANETA that affects NETs. This study aimed to determine the significance of anti-MYL6 antibody in MPA.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness and safety of rituximab (RTX) in treating microscopic polyangiitis and granulomatosis with polyangiitis in Japan over a 2-year period.
  • Out of 75 patients treated with RTX, 53 achieved remission within six months, but serious adverse events and infections were reported, leading to 9 deaths.
  • The study concludes that while RTX is effective for achieving remission, older patients and those with pulmonary complications are at a higher risk for serious infections.
View Article and Find Full Text PDF

Objectives: We conducted a Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of intravenous immunoglobulin (IVIg) in patients with glucocorticoid-refractory neuropathy associated with microscopic polyangiitis.

Methods: Patients received immunoglobulin or placebo intravenously for 5 consecutive days at baseline and after 4 weeks. The IVIg and placebo groups received IVIg and placebo, respectively, after 8 weeks.

View Article and Find Full Text PDF

Objectives: This study investigated the current practice of prophylactic treatment against Pneumocystis jirovecii pneumonia (PCP) and its effectiveness in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Methods: This study included 319 patients registered from 53 institutions in Japan and newly diagnosed with AAV. During the 2-year observation period, we examined the frequency of usage, effectiveness and safety of prophylactic drugs against PCP.

View Article and Find Full Text PDF

Background: The life prognosis of elderly patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies-associated vasculitis (MPO-AAV) has been improved by reducing the corticosteroid or cyclophosphamide dose to avoid opportunistic infection. However, many elderly MPO-AAV patients experience recurrence and renal death. An effective and safer maintenance treatment method is necessary to improve the renal prognosis of MPO-AAV.

View Article and Find Full Text PDF

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created as revised from J-SSCG 2016 jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in September 2020 and published in February 2021. An English-language version of these guidelines was created based on the contents of the original Japanese-language version. The purpose of this guideline is to assist medical staff in making appropriate decisions to improve the prognosis of patients undergoing treatment for sepsis and septic shock.

View Article and Find Full Text PDF
Article Synopsis
  • - The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020) were developed to help healthcare professionals effectively treat sepsis and septic shock, building on the previous guidelines from 2016.
  • - The guidelines cover 22 areas including important new topics such as patient-centered care and ICU-acquired weakness, and detail 118 clinical questions that address various aspects of sepsis management.
  • - In creating these guidelines, a diverse group of 226 medical professionals used the GRADE method for recommendations, resulting in 79 GRADE-based recommendations and 5 Good Practice Statements.
View Article and Find Full Text PDF

Background: We previously identified tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker of disease activity that distinguished mildly or highly active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) from remission 6 months after the initiation of remission-induction therapy. In the present study, we investigated whether TIMP-1 is clinically useful as a predictor of relapse and sustained remission in AAV patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) during maintenance therapy.

Methods: The relationship between serum TIMP-1 levels and clinical outcomes in AAV patients receiving maintenance therapy was assessed using the follow-up data of a Japanese large-cohort study (the RemIT-JAV-RPGN study) and data collected from AAV patients on maintenance therapy in our hospital (the MAAV-EU study).

View Article and Find Full Text PDF

A novel patient cluster in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may be identified in Japan. We performed multiple correspondence and cluster analysis regarding 427 clinically diagnosed AAV patients excluding eosinophilic granulomatosis with polyangiitis. Model 1 included the ANCA phenotype, items of the Birmingham Vasculitis Activity Score, and interstitial lung disease; model 2 included serum creatinine (s-Cr) and C-reactive protein (CRP) levels with model 1 components.

View Article and Find Full Text PDF

Background: Interstitial lung disease (ILD) is a severe complication with poor prognosis in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Prevalence of AAV-associated ILD (AAV-ILD) in Japan is considerably higher than that in Europe. Recently, we reported that a MUC5B variant rs35705950, the strongest susceptibility variant to idiopathic pulmonary fibrosis (IPF), was strikingly increased in AAV-ILD patients but not in AAV patients without ILD; however, due to the low allele frequency in the Japanese population, the MUC5B variant alone cannot account for the high prevalence of AAV-ILD in Japan.

View Article and Find Full Text PDF

Background: It is not elucidated that there is treatment-related damage in elderly patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Methods: Elderly (≥ 75 years of age) patients were enrolled from two nationwide prospective inception cohort studies. The primary outcome was 12-month treatment-related Vasculitis Damage Index (VDI) score.

View Article and Find Full Text PDF

Background: Steroid pulse therapy with tonsillectomy is known as a major treatment for IgA nephropathy (IgAN). However, its protocol was different among institutions and the effects of varying the number of steroid pulses remain unclear.

Methods: From a total of 1,174 IgAN patients in a multicenter retrospective cohort analysis in Japan, 195 patients were treated by tonsillectomy combined with corticosteroid.

View Article and Find Full Text PDF

Background: Rapidly progressive glomerulonephritis (RPGN) has been known to have a poor prognosis. Although evidence across adult RPGN cases has accumulated over many years, the number of case series in adolescents and young adults has been limited, requiring further studies.

Methods: A total of 1,766 cases from 1989 to 2007 were included in this nationwide questionnaire survey, led by Intractable (former name, Progressive) Renal Diseases Research, Research on intractable disease, from the Ministry of Health, Labour and Welfare of Japan.

View Article and Find Full Text PDF

Background: The detection of leukocyte-derived CD11b (α subunit of integrin Mac-1) and CD163 (scavenger receptor) in urine may reflect renal inflammation in antineutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN). The objective of this study was to evaluate the clinical significance of urinary CD11b (U-CD11b) and CD163 (U-CD163) in ANCA-GN.

Methods: U-CD11b and U-CD163 were examined using enzyme-linked immunosorbent assay in ANCA-GN urine samples from our institutional cohort (n = 88) and a nationwide cohort (n = 138), and their association with renal histology was subsequently analyzed.

View Article and Find Full Text PDF

Background: Relapses frequently occur in giant cell arteritis (GCA), and long-term glucocorticoid therapy is required. The identification of associated factors with poor treatment outcomes is important to decide the treatment algorithm of GCA.

Methods: We enrolled 139 newly diagnosed GCA patients treated with glucocorticoids between 2007 and 2014 in a retrospective, multi-center registry.

View Article and Find Full Text PDF